Literature DB >> 15772959

Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.

Osamu Sato1, Takuro Wada, Akira Kawai, Umio Yamaguchi, Atsushi Makimoto, Yasuo Kokai, Toshihiko Yamashita, Hirokazu Chuman, Yasuo Beppu, Yoichi Tani, Tadashi Hasegawa.   

Abstract

BACKGROUND: Little is known about the expression of receptor tyrosine kinases in adult soft tissue sarcomas (STS). In the current study, the authors analyzed the expression of epidermal growth factor receptor (EGFR), ERBB2, and KIT in 281 patients with STS who were treated in a single institution. Verification of the presence of an association with prognosis was performed.
METHODS: The current study included 281 adult patients with STS of the extremity and trunk who were diagnosed and treated in the National Cancer Center, Tokyo. Expression was assessed using immunohistochemical stains for EGFR, ERBB2, and KIT on formalin-fixed, paraffin-embedded tissue sections by standard avidin-biotin peroxidase complex technique and EGFR detection system.
RESULTS: Positive staining of EGFR was observed in 168 of 281 (60%) patients. Positive staining was common in pleomorphic malignant fibrous histiocytomas (89%), myxofibrosarcomas (89%), synovial sarcomas (76%), malignant peripheral nerve sheath tumors (89%), and leiomyosarcomas (73%). It was less common in well differentiated liposarcomas (38%), fibrosarcomas (36%), and myxoid liposarcomas (6%). In contrast, positive staining of ERBB2 and KIT was very limited. Increased levels of EGFR were significantly associated with a decreased probability of overall survival (P = 0.01), although by univariate analysis; probability of overall survival at 5 years was 64% in patients with increased levels of EGFR and 79% in patients without such overexpression. The overexpression of EGFR was significantly associated with histologic grade (P < 0.001). Moreover, stratified log-rank test revealed that there is an interrelation between EGFR overexpression and histologic grade.
CONCLUSIONS: EGFR overexpression was found to be a negative prognostic factor of adult STS, which is strongly associated with histologic grade. STS patients with EGFR overexpression may benefit from treatment with currently available biospecific inhibitors for EGFR. (c) 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772959     DOI: 10.1002/cncr.20986

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Development and evaluation of a connective tissue phantom model for subsurface visualization of cancers requiring wide local excision.

Authors:  Kimberley S Samkoe; Brent D Bates; Niki N Tselepidakis; Alisha V DSouza; Jason R Gunn; Dipak B Ramkumar; Keith D Paulsen; Brian W Pogue; Eric R Henderson
Journal:  J Biomed Opt       Date:  2017-12       Impact factor: 3.170

2.  Association between the HER2 expression and histological differentiation in Wilms tumor.

Authors:  M Salem; Y Kinoshita; T Tajiri; R Souzaki; K Tatsuta; M Higashi; T Izaki; K Kohashi; M Tsuneyoshi; T Taguchi
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

3.  Measuring microdose ABY-029 fluorescence signal in a primary human soft-tissue sarcoma resection.

Authors:  Kimberley S Samkoe; Hira Shahzad Sardar; Jason Gunn; Joachim Feldwisch; Konstantinos Linos; Eric Henderson; Brian Pogue; Keith Paulsen
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-05-22

4.  EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas.

Authors:  Alexcia Camila Braun; Celso Abdon Lopes de Mello; Marcelo Corassa; Emne Ali Abdallah; Ana Cláudia Urvanegia; Vanessa Silva Alves; Bianca C T C P Flores; Mônica Díaz; Ulisses Ribaldo Nicolau; Virgilio Souza E Silva; Vinicius Calsavara; Patrizia Paterlini-Brechót; Ludmilla Thomé Domingos Chinen
Journal:  Cancer Biol Ther       Date:  2018-03-21       Impact factor: 4.742

Review 5.  A young man with primary prostatic extra-gastrointestinal stromal tumor: a rare case report and review of the literature.

Authors:  Zhi-Hong Zhang; Guo-Wei Feng; Zhi-Fei Liu; Lei Qiao; Tao Zhang; Chao Gao; Yong Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 6.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

7.  Prognostic significance of Minichromosome maintenance protein 7 and Geminin expression in patients with 109 soft tissue sarcomas.

Authors:  Yuki Hamamoto; Kohei Shomori; Kanae Nosaka; Tomohiro Haruki; Ryota Teshima; Hisao Ito
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

8.  Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas.

Authors:  C Kersting; J Packeisen; B Leidinger; B Brandt; R von Wasielewski; W Winkelmann; P J van Diest; G Gosheger; H Buerger
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

Review 9.  Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection.

Authors:  Joseph A Ludwig
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

10.  Expression and significance of EGFR in malignant peripheral nerve sheath tumor.

Authors:  Daniel Keizman; Josephine Issakov; Isaac Meller; Natalie Maimon; Natalie Meimon; Maya Ish-Shalom; Osnat Sher; Ofer Merimsky
Journal:  J Neurooncol       Date:  2009-03-28       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.